Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effektiviteten av transkutan NMES som ett tillägg för sväljningsstörningar hos trakeotomerade patienter (SWALEC)

18 september 2026 uppdaterad av: Hopital Forcilles

Utvärdering av effektiviteten av transkutan neuromuskulär elektrisk stimulering som ett komplement till standardbehandling för sväljningsstörningar hos trakeotomerade patienter efter långvarig avvänjning från mekanisk ventilation

Dysphagia can reach a prevalence of up to 80% in intensive care patients. The implementation or prolonged presence of medical devices such as the intubation tube, tracheostomy, or nasogastric tube alters the physiology of swallowing and causes local injuries at several levels. Additionally, certain medical treatments impair swallowing physiology and the patient's alertness, further promoting the development of these disorders.

Management of dysphagia involves two main types of strategies: adaptive or compensatory maneuvers and rehabilitation techniques such as: performing praxis or swallowing exercises; physical stimulation (tactile or thermal); transcranial stimulation (electrical or magnetic); and finally, pharyngeal or transcutaneous electrical stimulation (NMES).

Patients hospitalized in intensive care often present with altered levels of alertness, asynchronous ventilation and swallowing, and reduced motor capabilities, making it difficult to perform techniques like praxis, food trials, or resistance swallowing exercises. NMES does not require active patient cooperation or the permanent presence of the therapist during the stimulation session, thus increasing the intensity of dysphagia rehabilitation and the early implementation of treatment in these patients, complementing conventional rehabilitation. Muscle and sensory stimulation through the application of NMES can help increase the strength of the muscles involved in swallowing and improve sensory capabilities. However, its effects have not yet been evaluated in tracheostomized patients undergoing weaning from prolonged mechanical ventilation.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

238

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Hospitalized in intensive care units, post-ICU rehabilitation, or weaning and rehabilitation services;
  • Presence of a tracheostomy for more than 72 hours due to difficult mechanical ventilation weaning;
  • Diagnosis of swallowing disorders (swallowing fiberoscopy);
  • Patient aged at least 18 years at the time of inclusion;
  • Affiliated to a social security scheme or beneficiary of such a scheme;
  • Written, free and informed consent of the patient or their next of kin.

Exclusion Criteria:

  • Contra- indication to cervical NMES;
  • History of swallowing disorders;
  • Patient with a spinal cord injury above C5 level;
  • History of head and neck cancer;
  • Person under legal protection measures;
  • Patient under guardianship or conservatorship;
  • Known pregnancy;
  • Limitation of care.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo Neuromuscular Electrical Stimulation (Placebo NMES)

Patients included in the control group will receive standard care and the control intervention. The Neuro Muscular Electrical Stimulation (NMES) will be applied through 2 pairs of electrodes to the anterior surface of the neck. The same frequency and pulse duration will be used. The intensity will be increased until a vibration/tingling sensation perceptible by the patient is produced. The device will then be turned off.

NMES will be applied via two pairs of electrodes on the anterior neck.

Two electrodes will be placed above the hyoid bone, on either side, between the hyoid bone and the mandible. The other two electrodes will be placed on either side of the thyroid cartilage.

The patient will also be comfortably positioned in a supine position, with the backrest inclined at 45°. The same frequency and pulse duration will be used. The intensity will be increased until the patient perceives a vibrating/tingling sensation. The device will then be turned off.

The control intervention begins at least 72 hours after the tracheotomy and lasts for 21 days, with daily 30-minute sessions, five days per week.

The treatment is administered once per day at a time slot chosen by each center.

Experimentell: Neuromuscular Electrical Stimulation (NMES)

The patient is comfortably positioned on their back, with the backrest at a 45° incline. Neuromuscular electrical stimulation (NMES) is applied through two pairs of electrodes placed on the front of the neck: one pair on the supra-hyoid muscles and the other on the infra-hyoid muscles. The electrodes are positioned using anatomical landmarks of the hyoid bone and the mandible. A current of 80 Hz with a pulse duration of 700 µs is applied to induce a muscle contraction. The treatment begins at least 72 hours after the tracheotomy and lasts for 21 days, with daily 30-minute sessions, 5 days a week. The treatment is performed once per day.

Let me know if you need further adjustments or explanations!

The patient will be comfortably positioned on their back, with the backrest inclined at 45°.

NMES will be applied via two pairs of electrodes on the anterior neck. One pair of electrodes will be placed on the suprahyoid muscles and the other on the infrahyoid muscles.

The treatment begins at least 72 hours after the tracheotomy and lasts for 21 days, with daily 30-minute sessions, five days per week. The treatment is administered once per day. Each department is encouraged to identify a time slot to facilitate the organization of care and avoid non-completion of the treatment.

The duration of the session and the frequency of the intervention's application were chosen based on data from a recent systematic review of randomized controlled trials comparing the effectiveness of NMES versus conventional treatment. The included studies mostly had session durations around 30 minutes, 2 to 5 times per week, for a period of 2 to 6 weeks.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Prevalence of swallowing disorders after 21 days of NMES of the suprahyoid and infrahyoid muscles as an adjunct to standard treatments, in patients following tracheotomy due to prolonged mechanical ventilation weaning
Tidsram: after 21 days of treatment

Evaluate the effectiveness of NMES of the suprahyoid and infrahyoid muscles as an adjunct to standard treatments for swallowing disorders, on the prevalence of these disorders after 21 days of treatment, in patients who have undergone tracheotomy due to prolonged mechanical ventilation weaning.

after 21 days of treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Severity of swallowing disorders - the yale pharyngeal residue severity rating scale
Tidsram: 21 days

Comparatively evaluate the effectiveness of NMES of the suprahyoid and infrahyoid muscles as an adjunct to standard treatments for swallowing disorders in patients who have undergone tracheotomy due to prolonged mechanical ventilation weaning on the severity of swallowing disorders at 21 days of NMES as an adjunct to standard treatments, in patients following tracheotomy. Unit of Measure: the yale pharyngeal residue severity rating scale rated by a speech-language therapist based on fiberoptic endoscopic evaluation of swallowing (FEES). This assessments by a speech-language therapist blinded to group allocation.

21 days
Time to resume oral feeding at Day 21 after NMES initiation
Tidsram: At day 21 after initiation of NMES/placebo

Description:

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on time to resume oral feeding within 21 days in tracheotomized patients following prolonged mechanical ventilation weaning. Time will be measured in days. In routine practice, all changes in the patient's dietary intake are recorded daily by medical, dietitians and nursing staff. Data collected from the patient's electronic medical record by a clinical research technician.

At day 21 after initiation of NMES/placebo
Duration of mechanical ventilation
Tidsram: Day 21 after initiation of NMES treatment/placebo

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on the duration of mechanical ventilation. Data collected from the patient's electronic medical record by a clinical research technician.

Day 21 after initiation of NMES treatment/placebo
Lenght of stay
Tidsram: From study inclusion (Day 0) until discharge from the intensive care unit or post-intensive care unit, assessed up to study completion (approximately 30 days)

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on length of stay in the intensive care unit. Length of stay will be measured in days and collected from the electronic medical records by a trained clinical research technician.

From study inclusion (Day 0) until discharge from the intensive care unit or post-intensive care unit, assessed up to study completion (approximately 30 days)
Time to tracheostomy decannulation
Tidsram: From study inclusion (Day 0) until tracheostomy decannulation, assessed up to study completion (approximately 30 days)

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on time to tracheotomy decannulation. Time will be measured in days. Data will be collected from the electronic medical records by a trained clinical research technician.

From study inclusion (Day 0) until tracheostomy decannulation, assessed up to study completion (approximately 30 days)
Prevalence of malnutrition
Tidsram: At day 21 after initiation NMES treament/place

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on the prevalence of malnutrition at Day 21. Prevalence of malnutrition will be expressed as a percentage of patients meeting predefined diagnostic criteria (French national recommendations on malnutrition diagnostic evaluation)

At day 21 after initiation NMES treament/place
Prevalence of malnutrition at unit discharge
Tidsram: At study end, defined as discharge from the intensive care unit or post-intensive care unit, assessed up to study completion (approximately 30 days)

Comparative evaluation of the effectiveness of neuromuscular electrical stimulation (NMES) of the suprahyoid and infrahyoid muscles, as an adjunct to standard care, on the prevalence of malnutrition at unit discharge. Prevalence of malnutrition will be expressed as a percentage of patients meeting predefined diagnostic criteria (French national recommendations on malnutrition diagnostic evaluation)

At study end, defined as discharge from the intensive care unit or post-intensive care unit, assessed up to study completion (approximately 30 days)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Carlos Diaz Lopez, Hopital Forcilles

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 juni 2028

Avslutad studie (Beräknad)

30 juni 2028

Studieregistreringsdatum

Först inskickad

13 januari 2026

Först inskickad som uppfyllde QC-kriterierna

9 april 2026

Första postat (Faktisk)

14 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera